COVAXIN clinical trials recruit 23,000 subjects
COVAXIN has been evaluated in approximately 1000 subjects in Phase I and Phase II clinical trials, with promising safety and…
Sign in
Sign in
Recover your password.
A password will be e-mailed to you.
Browsing Tag
Bharat Biotech
SEC recommends EUA for Covaxin from Bharat Biotech
The expert panel deliberated on Bharat Biotech’s EUA application after it submitted additional data, facts and analysis after…
SEC meets to discuss EUA applications from Pfizer, SII and Bharat Biotech
To reconvene on Jan 1, 2021
India has key role to play in equitable distribution of COVID-19 vaccines: Industry experts
Experts bat for global cooperation and coordination to tackle COVID-19 pandemic
Vice President Venkaiah Naidu meets Bharat Biotech CMD, discusses status of Covaxin
Naidu stressed the importance of PPPs in coming out with indigenous world-class products
Phase I clinical trial outcome shows Covaxin generates antibody, T-cell memory response
we hypothesize that BBV152 can generate antibodies that may persist for 6-12 months.
COVAXIN is well tolerated with no serious adverse events in Phase I trials
The trial was conducted on volunteers from diverse geographic locations and socioeconomic conditions, enrolling 375 participants…
COVID-19 expedites India’s focus on innovation within pharma: GlobalData
According to the Global Innovation Index, India has moved up four places to 48 in the overall ranking across sectors in 2020
Team of 70 Ambassadors and High Commissioners visit Bharat Biotech, discuss COVAXIN
COVAXIN has been evaluated in approximately 1000 subjects in Phase I and Phase II clinical trials, with promising safety and…
Bharat Biotech seeks EUA for Covaxin
No date has been fixed as on when the SEC will meet for assessing and evaluating the applications, as per sources